February 15, 2012 10:22 AM | 29 seconds read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The FDA has approved theaddition of a secondary supplier of Methoxsalen USP, an integral component ofa treatment for the relief of moderate to severe psoriasis prescribed underthe brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg. "We are pleased to obtain FDA approval of an additional manufacturer ofMethoxsalen, the key active ingredient for this important drug," said DavidMullarkey, senior vice president and general manager of Valeant Dermatology, adivision of Valeant Pharmaceuticals North America LLC. "This approval enablesus to ensure a steady supply of Oxsoralen-Ultra and is a key step in restoringthe supply of our other Methoxsalen containing drug products."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.